Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Rational Vaccine Design to prevent HIV-Associated Lymphoma

Award Number: R01CA285227
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2024
PERIOD OF PERFORMANCE END DATE: 01/31/2029

Group Awards By:

View Award Description

Rational Vaccine Design to prevent HIV-Associated Lymphoma - PROJECT SUMMARY/ABSTRACT Relative to the general population, HIV-infected individuals have a 60–200-fold higher relative risk to develop Non-Hodgkin's Lymphomas, including plasmablastic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma and diffuse large B-cell lymphoma. They also have an 8–10-fold higher relative risk to develop Hodgkin's Lymphoma compared to uninfected individuals. Many of these malignancies are driven by Epstein-Barr virus (EBV) and result from poor immune control of the virus driven by HIV- dependent immune dysfunction. Thus, a safe and effective vaccine that prevents EBV infection and eliminates the EBV-associated component of risk could have a significant clinical benefit in resource-poor areas where HIV-1 is endemic. The correlate of protection for most successful viral vaccines is neutralizing antibodies. Previously, our lab isolated the first anti-EBV mAb that could potently neutralize infection of both B cells and epithelial cells. We further demonstrated that passive transfer of AMMO1 protected both humanized mice and rhesus macaques from experimental EBV infection. These results strongly suggest that antibodies are important for, if not sufficient to protect against EBV infection, and that a prophylactic vaccine should seek to elicit high titers of AMMO1-like antibodies. To this end, we developed and tested several gH/gL vaccines. All gH/gL vaccines were strongly immunogenic, but they only showed partial protection against experimental EBV infection in humanized mice and macaques. Epitope mapping studies revealed that vaccine-elicited gH/gL antibodies targeting the AMMO1 epitope were subdominant and rare, while antibodies targeting other non- neutralizing epitopes on gH/gL were immunodominant. The goal of this proposal is to obtain a high-resolution antigenic landscape of the gH/gL glycoprotein to define the most critical sites of vulnerability. We will then use this this information to employ structure guided EBV vaccine design intended to immunofocus the antibody response onto protective epitopes like the one targeted by AMMO1, and evaluate their ability to protect against EBV challenge in humanized mice and macaques.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $560,212 )
2026	2026	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Cause and Prevention Research	000	3	1/30/2026	NON-COMPETING CONTINUATION	$560,212
														Subtotal = $560,212

Issue Date FY: 2025 ( Subtotal = $647,437 )
2025	2025	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Cause and Prevention Research	001	2	5/22/2025	NON-COMPETING CONTINUATION	$0
2025	2025	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Cause and Prevention Research	000	2	3/4/2025	NON-COMPETING CONTINUATION	$647,437
														Subtotal = $647,437

Issue Date FY: 2024 ( Subtotal = $664,754 )
2024	2024	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Cancer Cause and Prevention Research	000	1	1/29/2024	NEW	$664,754
														Subtotal = $664,754

Grand Total All Awards = $1,872,403

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Rational Vaccine Design to prevent HIV-Associated Lymphoma

Award Number: R01CA285227

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2024

PERIOD OF PERFORMANCE END DATE: 01/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer